Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

NCT05692024 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05692024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05692024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 21, 2024
Completion date
August 31, 2028
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coffee, colorectal cancer, fibrosis, liver, gastrointestinal microbiome, proton magnetic resonance spectroscopy, stenosis, ultrasound elastography